XML 147 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Compensation Expense and Related Income Tax benefit
The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):
 Year Ended December 31,
Compensation costs and related income tax benefit202020192018
Cost of sales$6 $4 $4 
Selling and marketing16 17 13 
Research and development16 16 15 
General and administration21 23 21 
Total compensation expense$59 $60 $53 
Income tax benefit$9 $9 $10 
Summary of SARs Activity A summary of the Company’s SARs outstanding is as follows:
202020192018
SARsSARsWeighted-
Average
Exercise 
Price		SARsWeighted-
Average
Exercise 
Price		SARsWeighted-
Average
Exercise 
Price
Outstanding at beginning of year896,923 $89.05 1,261,185 $75.71 1,817,991 $65.73 
Granted69,742 253.62 70,141 205.12 88,042 149.75 
Exercised(295,770)67.96 (395,015)66.82 (598,249)55.93 
Forfeited(31,193)149.09 (39,388)92.72 (46,161)80.41 
Expired(1,578)166.52 — — (438)108.20 
Outstanding at end of year638,124 $113.98 896,923 $89.05 1,261,185 $75.71 
Exercisable at end of year417,856 $81.88 489,357 $70.37 595,086 $60.85 
Schedule of Weighted-Average Assumptions Used for Grants of SARs
The following table shows the weighted-average assumptions used for grants of SARs, as well as the fair value of the grants based on those assumptions:
 202020192018
Expected dividend yield0%0%0%
Forfeiture rate8.00%8.20%8.40%
Volatility42.51%36.79%35.93%
Risk free interest rate0.24%2.28%2.96%
Expected weighted-average life4.004.024.11
Weighted-average grant date fair value of SARs granted
(per underlying share)		$79.47$64.17$47.63
Summary of Outstanding and Exercisable Options
A summary of the Reflexis Replacement Options outstanding is as follows:
 2020
Reflexis Replacement OptionsSharesWeighted-
Average
Exercise Price
Outstanding at beginning of year— $— 
Granted38,228 57.82 
Exercised(3,408)55.79 
Forfeited(396)52.14 
Expired— — 
Outstanding at end of year34,424 $58.09 
Exercisable at end of year6,716 $56.77 
The following table summarizes information about the Reflexis Replacement Options outstanding as of December 31, 2020:
OutstandingExercisable
Aggregate intrinsic value (in millions)$11 $2
Weighted-average remaining contractual life7.47.3
Summary of Restricted Stock Award Activity
A summary of information relative to the Company’s RSAs is as follows:
 202020192018
RSAsSharesWeighted-Average
Grant Date Fair Value		SharesWeighted-Average
Grant Date Fair Value		SharesWeighted-Average
Grant Date Fair Value
Outstanding at beginning of year434,641 $151.52 657,724 $93.45 628,642 $77.70 
Granted178,150 265.06 170,502 204.26 206,922 150.60 
Released(275,318)133.43 (372,075)73.71 (154,878)107.22 
Forfeited(18,908)199.04 (21,510)141.29 (22,962)88.77 
Outstanding at end of year318,565 $228.08 434,641 $151.52 657,724 $93.45 
Summary of Performance Share Award Activity
A summary of information relative to the Company’s PSAs is as follows:
 202020192018
PSAsSharesWeighted-Average
Grant Date Fair Value		SharesWeighted-Average
Grant Date Fair Value		SharesWeighted-Average
Grant Date Fair Value
Outstanding at beginning of year170,749 $144.47 259,727 $86.41 265,747 $77.04 
Granted98,820 239.79 150,224 206.04 59,849 146.83 
Released(131,943)160.18 (231,513)120.86 (57,074)107.31 
Forfeited(11,604)194.23 (7,689)102.42 (8,795)81.07 
Outstanding at end of year126,022 $199.77 170,749 $144.47 259,727 $86.41 
Summary of Information for SARs Outstanding
The following table summarizes information about SARs outstanding as of December 31, 2020:
OutstandingExercisable
Aggregate intrinsic value (in millions)$173$126
Weighted-average remaining contractual life4.44.2